[go: up one dir, main page]

BR0311674A - processo para a preparação de compostos - Google Patents

processo para a preparação de compostos

Info

Publication number
BR0311674A
BR0311674A BRPI0311674-3A BR0311674A BR0311674A BR 0311674 A BR0311674 A BR 0311674A BR 0311674 A BR0311674 A BR 0311674A BR 0311674 A BR0311674 A BR 0311674A
Authority
BR
Brazil
Prior art keywords
compounds
preparation
formula
chaineded
cycloalkanes
Prior art date
Application number
BRPI0311674-3A
Other languages
English (en)
Inventor
Karl Jansson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of BR0311674A publication Critical patent/BR0311674A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PROCESSO PAPA A PREPARAçãO DE COMPOSTOS. Um processo para a preparação dos compostos da fórmula geral (I) reagindo um derivado de éster de ácido quinolina-3- carboxílico da fórmula A com um derivado de anilina da fórmula B em um solvente selecionado de alcanos e cicloalcanos de cadeia reta ou ramificada ou misturas destes com um ponto de ebulição entre 80 e 200<198>C.
BRPI0311674-3A 2002-06-12 2003-05-14 processo para a preparação de compostos BR0311674A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives
PCT/SE2003/000780 WO2003106424A1 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives

Publications (1)

Publication Number Publication Date
BR0311674A true BR0311674A (pt) 2008-01-08

Family

ID=20288148

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311674-3A BR0311674A (pt) 2002-06-12 2003-05-14 processo para a preparação de compostos

Country Status (28)

Country Link
EP (1) EP1511732B9 (pt)
JP (1) JP4584709B2 (pt)
KR (1) KR100979216B1 (pt)
CN (1) CN100418950C (pt)
AT (1) ATE348814T1 (pt)
AU (1) AU2003228195B2 (pt)
BR (1) BR0311674A (pt)
CA (1) CA2487329C (pt)
CY (1) CY1107555T1 (pt)
DE (1) DE60310554T2 (pt)
DK (1) DK1511732T5 (pt)
ES (1) ES2278160T3 (pt)
HR (1) HRP20050028B1 (pt)
IL (1) IL165155A (pt)
IS (1) IS2975B (pt)
ME (1) ME00435B (pt)
MX (1) MXPA04012276A (pt)
NO (1) NO329162B1 (pt)
NZ (1) NZ536768A (pt)
PL (1) PL210259B1 (pt)
PT (1) PT1511732E (pt)
RS (1) RS51021B (pt)
RU (1) RU2291861C2 (pt)
SE (1) SE0201778D0 (pt)
SI (1) SI1511732T1 (pt)
UA (1) UA78310C2 (pt)
WO (1) WO2003106424A1 (pt)
ZA (1) ZA200409430B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2007047863A2 (en) * 2005-10-19 2007-04-26 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
MX2008015808A (es) * 2006-06-12 2009-02-17 Teva Pharma Preparaciones de laquinimod estable.
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
ES2600920T3 (es) 2007-12-20 2017-02-13 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
CN102143949A (zh) 2008-09-03 2011-08-03 泰华制药工业有限公司 2-羰基-1，2-二氢喹啉免疫功能调节剂
EP2376456A2 (en) * 2008-12-17 2011-10-19 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
CA2769623A1 (en) 2009-07-30 2011-02-03 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod
ME02495B (me) 2009-08-10 2017-02-20 Teva Pharma Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
MX337614B (es) 2010-03-03 2016-03-10 Teva Pharma Tratamiento de lupus nefritis usando laquinimod.
CA2791709A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
CA2804989A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EP3213636A1 (en) 2010-07-09 2017-09-06 Teva Pharmaceutical Industries, Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
NZ604176A (en) * 2010-07-09 2014-10-31 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
KR20140138694A (ko) 2012-02-03 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
AU2014236232A1 (en) * 2013-03-14 2015-11-05 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
CA2945978A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
JP6647287B2 (ja) 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
CA2967112C (en) 2014-11-19 2023-05-16 Active Biotech Ab Quinoline carboxamides for use in the treatment of leukemia
BR112022016873A2 (pt) 2020-03-03 2022-10-25 Active Biotech Ab Combinação, kit, e, tasquinimod ou um sal farmaceuticamente aceitável do mesmo para uso no tratamento de mieloma múltiplo
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
CN116782902A (zh) 2020-07-23 2023-09-19 伊拉兹马斯大学鹿特丹医学中心 作为骨髓增殖性肿瘤中的新治疗靶标的s100蛋白
AU2022208424A1 (en) 2021-01-18 2023-08-24 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
CA3218977A1 (en) 2021-05-25 2022-12-01 Hans Wannman A plurality of tasquinimod particles and use thereof
EP4363404A1 (en) 2021-07-02 2024-05-08 Active Biotech AB A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
RS107604A (en) 2007-02-05
NO329162B1 (no) 2010-08-30
EP1511732B9 (en) 2008-11-12
NO20045703L (no) 2004-12-29
DK1511732T3 (da) 2007-04-30
AU2003228195B2 (en) 2009-05-28
IS2975B (is) 2017-07-15
WO2003106424A1 (en) 2003-12-24
CA2487329A1 (en) 2003-12-24
NZ536768A (en) 2006-10-27
EP1511732A1 (en) 2005-03-09
JP2005535612A (ja) 2005-11-24
RU2005100054A (ru) 2005-07-10
JP4584709B2 (ja) 2010-11-24
PL210259B1 (pl) 2011-12-30
SE0201778D0 (sv) 2002-06-12
DK1511732T5 (da) 2007-10-01
HRP20050028A2 (en) 2006-02-28
PT1511732E (pt) 2007-03-30
UA78310C2 (en) 2007-03-15
MXPA04012276A (es) 2005-04-08
SI1511732T1 (sl) 2007-06-30
IL165155A (en) 2009-11-18
EP1511732B1 (en) 2006-12-20
ATE348814T1 (de) 2007-01-15
CN1659146A (zh) 2005-08-24
KR20050016537A (ko) 2005-02-21
ZA200409430B (en) 2006-02-22
CN100418950C (zh) 2008-09-17
AU2003228195A1 (en) 2003-12-31
RU2291861C2 (ru) 2007-01-20
ME00435B (me) 2011-10-10
RS51021B (sr) 2010-10-31
KR100979216B1 (ko) 2010-08-31
CA2487329C (en) 2010-11-16
CY1107555T1 (el) 2013-03-13
IS7550A (is) 2004-11-24
IL165155A0 (en) 2005-12-18
DE60310554T2 (de) 2007-11-29
DE60310554D1 (de) 2007-02-01
PL373817A1 (en) 2005-09-19
HRP20050028B1 (hr) 2013-07-31
ES2278160T3 (es) 2007-08-01

Similar Documents

Publication Publication Date Title
BR0311674A (pt) processo para a preparação de compostos
HRP20040690B1 (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
EA200500103A1 (ru) Новые производные бензимидазола
BRPI0415855B1 (pt) Processo para preparação de ésteres de ácido 2-dihalogenacil-3-amino-acrílico e ésteres de ácido 3-dihalogeno-metil-pirazol-4-carboxílico
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
BR0215027A (pt) Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação
NO20054787L (no) Indenderivater som farmasotiske midler
BR0213481A (pt) Sondas
BR0308345A (pt) Processo para derivados de ácido trans-4-amino-1-cicloexanocarboxìlico
BR9506727A (pt) Processo para a recemização do substrato de piperazino-2-terc-butil-carboxamida e composto
BR0315671A (pt) Processo para a preparação de um composto
SE0201938D0 (sv) New process
SE0003186D0 (sv) New process
DE60322886D1 (de) Verfahren zur herstellung von benzamideverbindungen mit einer aminomethylgruppe
BR0315508A (pt) Processo para preparação de compostos de pirazol
BR0211749B1 (pt) processo para a preparação de derivados de 4-(imidazol-1- il)benzenossulfonamida
DK1423385T3 (da) Mellemprodukter til fremstilling af neuraminidaseinhibitorkonjugater
TW200621807A (en) Cellulose derivative composition, cellulose derivative film and trialkoxybenzoic acid deriv ative compound
TH72657A (th) สารประกอบ
NO20044045L (no) Ny fremgangsmate
DE50110830D1 (de) Beschichtungen aus speziellen polyolen und oxalsäure
BRPI0415348A (pt) processo para preparação de 3beta-aminonortropanos n-substituìdos
DE60128336D1 (de) Eine zwischenverbindung und verfahren zu deren herstellung
IS8017A (is) Nítratesterar fenýlamínóþíófenediksýruafleiða
TH64772A (th) อนุพันธ์ของกรดฮาโลจีเนต 2-อะมิโน-4,5 เฮพทีในอิกที่ใช้เป็นตัวยับยั้งไนตริกออกไซด์ซินเทส

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/4706, A61P 37/04, C07D 215/56, C07D 491/04

Ipc: C07D 215/56 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements